Developer docs
API playgroundTry for free, no card

Search company profiles

Leaderna Biostructures

Full company profile

uuid000wimp

Namestring
Leaderna Biostructures
Legal namestring
Leaderna Biostructures Sp. z o.o.
Websiteurl
leaderna.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Leaderna Biostructures Sp. z o.o. is a privately held Polish structural-biology contract research organization founded in 2020 by Pawel Kustosz and headquartered at the University of Warsaw's Biological and Chemical Research Centre (CNBCh UW) in Warsaw. The firm delivers high-resolution 3D structure determination services for pharmaceutical and biotechnology clients engaged in structure-based drug design, with a particular specialization in protein–nucleic acid complexes developed through cooperation with IONIS Pharmaceuticals.

The company's core offering is the "Gene-to-Structure" pipeline, an integrated workflow covering expression-construct design, recombinant protein production, crystallization and X-ray diffraction (including synchrotron measurements), single-particle cryo-EM on Glacios 200 kV and Titan Krios 300 kV microscopes, and biophysical/biochemical characterization of target-ligand interactions. A proprietary site-specific cross-linking technology enables stabilization of transient and unstable protein–DNA/RNA complexes that resist standard co-crystallization. Leaderna positions as the first commercial cryo-EM provider in Poland and is built around a small bench of domain experts (CEO Kustosz, CSO Agnieszka Napiórkowska, CFO Sylwester Pobiarzyn, BD Przemysław Putno), with deep ties to the International Institute of Molecular and Cell Biology in Warsaw and Polish science centers.

Commercially, Leaderna operates a B2B service model selling directly to pharmaceutical companies across Poland, the Netherlands, and the United States. Revenue is generated through project-based structure-determination engagements priced under a risk-sharing model (preliminary experiments at operational cost, with success-fee structuring upon satisfactory delivery), supplemented by an EU funds assistance service where Leaderna acts as co-contractor or subcontractor on grant-funded crystallography programs. The named customer base spans IONIS Pharmaceuticals, UbiQ Bio, Adamed Pharma, Celon Pharma, OncoArendi Therapeutics, and Selvita, with cumulative disclosed project outputs of 13 protein-inhibitor structures solved for OncoArendi (whose OATD-01 compound is in clinical trials for sarcoidosis) and four structures solved for Adamed.

Short descriptiontext

Leaderna Biostructures is a Warsaw-based structural biology CRO providing X-ray crystallography and cryo-EM services (Gene-to-Structure pipeline) to pharmaceutical and biotechnology companies for structure-based drug design, with specialization in protein-nucleic acid complexes and a risk-sharing, success-fee pricing model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWarsaw, Poland
HQ citystring
Warsaw
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
structural biology services, X-ray crystallography, cryo-EM services, protein structure analysis, drug discovery services
Industry1 code
PRIMARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Structural Biology Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Structural Biology Services
TypeProfessional Services
Description

Service-based revenue from X-ray crystallography and cryo-EM analysis, including protein production, crystallization, structure determination, and biophysical characterization. Projects start with feasibility assessment followed by preliminary experiments at operational cost (risk-sharing model), with final payment as success fee upon satisfactory delivery.

leaderna.com
2EU Funded Project Services
TypeProfessional Services
Description

Assistance in obtaining EU funds for crystallography-based drug discovery, where Leaderna serves as co-contractor or subcontractor.

leaderna.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Leaderna Biostructures delivers Gene-to-Structure structural biology services for pharmaceutical and biotechnology drug discovery, covering gene construct design, recombinant protein production, crystallization, X-ray diffraction, cryo-EM analysis, and biophysical/biochemical characterization of protein-ligand interactions. The company specializes in structure-based drug design, with particular expertise in protein-nucleic acid complexes developed through cooperation with Ionis Pharmaceuticals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Minimizes screening of thousands or millions of chemicals for protein tailoring
+2 more records
Product overview1 text field

Leaderna Biostructures offers a unified service platform called Gene-to-Structure that provides end-to-end structural biology solutions for drug discovery. The platform integrates multiple service modules: Preparation of Expression Constructs, Recombinant Protein Production, X-ray Crystallography, Single-Particle Cryo-EM, and Biophysical and Biochemical Assays. A proprietary Unique Cross-linking Technology enables analysis of challenging protein-nucleic acid complexes. The services support structure-based drug design, hit-to-lead optimization, and lead optimization, with emphasis on nucleic acid-based therapeutics. Leaderna also provides EU Funds Assistance as a supporting service for funding applications.

Product and service2 records
1Gene-to-Structure Services
CategoryCore structural biology service offering
Description

Comprehensive end-to-end structural biology service covering gene construct design, recombinant protein expression and purification, crystallization, X-ray diffraction and cryo-EM data collection, structure determination and refinement, and biophysical and biochemical characterization of target-ligand interactions. Designed for pharmaceutical and biotechnology companies engaged in structure-based drug design, hit-to-lead optimization, and lead optimization.

2EU Funds Assistance Services
CategoryFunding support service
Description

Service that assists small and medium pharmaceutical companies in obtaining EU funding for crystallography-based new molecule discovery projects. Leaderna collaborates with technology transfer centers and serves as co-contractor or subcontractor in EU-funded projects, providing structural biology expertise within grant-funded drug discovery consortia.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration for solving protein-nucleic acid drug structures and joint patent development. This partnership expanded Leaderna's expertise in structure determination of nucleic acid-based drugs with proteins, positioning the company as a specialist in RNA-targeted therapeutics structural analysis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for solving protein-inhibitor structures and scientific cooperation using cryo-EM technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for solving protein-inhibitor structures. Four structures have been solved with results to be published.

4Celon Pharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on protein production and biophysical characterization under the prestigious InnoNeuroPharm NCBR grant.

leaderna.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for solving protein-inhibitor structures. 13 structures have been solved with results to be published. The OATD-01 compound from this collaboration is in clinical trials as a potential first-in-class sarcoidosis drug.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cooperation in structure-based drug design projects with leading pharmaceutical company in central Europe.

7Polish Science Centers
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Close collaboration with renowned experts and distinguished scientists in structural biology from Polish science centers, enabling execution of challenging projects.

leaderna.com
8International Institute of Molecular and Cell Biology in Warsaw (IIMCB)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founder Pawel Kustosz led the IIMCB Structure Biology Center from 2015-2020. The company operates from the University of Warsaw Biological and Chemical Research Centre, maintaining close ties with this research institution.

leaderna.com
9Technology Transfer Centers
Strategic tierMinorTypeGTM or Marketing Partner
Description

Cooperation with technology transfer centers to assist clients in obtaining EU funds for crystallography-based drug discovery projects.

leaderna.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Germany-based structural biology CRO offering X-ray crystallography and cryo-EM services for structure-based drug design; closest direct competitor to Leaderna with similar end-to-end structural biology workflow and pharma/biotech customer base.

TypeBroad incumbent
Description

Global drug discovery CRO with structural biology and protein sciences capabilities embedded within its integrated discovery platform — broad incumbent overlapping with Leaderna's structure-based drug design services.

TypeBroad incumbent
Description

UK-based integrated drug discovery CRO with structural biology, biophysics, and medicinal chemistry services — competes with Leaderna for structural biology engagements within broader discovery programs.

TypeOthers
Description

Host institution where Leaderna is physically located and which provides access to advanced cryo-EM and synchrotron-linked infrastructure; functions as both an enabler and a potential non-commercial alternative for academic clients.

TypeDirect peer
Description

Structural biology services provider offering protein crystallization, X-ray crystallography, cryo-EM, and protein production — directly competing in the same commercial service category as Leaderna.

TypeBroad incumbent
Description

Large global CRO offering structural biology and drug discovery services as part of a much broader portfolio; competes with Leaderna for enterprise pharma structural biology budgets but at significantly greater scale.

TypeDirect peer
Description

Sweden-based CRO specializing in protein crystallography, cryo-EM, and biophysical characterization for drug discovery — directly comparable service offering and target customers to Leaderna.

TypeBroad incumbent
Description

Large China-based discovery and development services organization with structural biology capabilities; competes in the structural biology services market and serves global pharma clients.

9Life Sciences Discovery (e.g., Concept Life Sciences / Domainex)
TypeRegional player
Description

UK-based discovery CROs with structural biology and protein science capabilities; comparable service offerings to Leaderna but operating in a different European geography.

TypeBroad incumbent
Description

Drug discovery company with heritage in structure-based design (Vernalis) and integrated with HitGen's platform; offers structure-based design services comparable to Leaderna's niche.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Leaderna Biostructures

Structural Biology Servicesleaderna.com

Leaderna Biostructures is a Warsaw-based structural biology CRO providing X-ray crystallography and cryo-EM services (Gene-to-Structure pipeline) to pharmaceutical and biotechnology companies for structure-based drug design, with specialization in protein-nucleic acid complexes and a risk-sharing, success-fee pricing model.

What Leaderna Biostructures does

Leaderna Biostructures Sp. z o.o. is a privately held Polish structural-biology contract research organization founded in 2020 by Pawel Kustosz and headquartered at the University of Warsaw's Biological and Chemical Research Centre (CNBCh UW) in Warsaw. The firm delivers high-resolution 3D structure determination services for pharmaceutical and biotechnology clients engaged in structure-based drug design, with a particular specialization in protein–nucleic acid complexes developed through cooperation with IONIS Pharmaceuticals.

The company's core offering is the "Gene-to-Structure" pipeline, an integrated workflow covering expression-construct design, recombinant protein production, crystallization and X-ray diffraction (including synchrotron measurements), single-particle cryo-EM on Glacios 200 kV and Titan Krios 300 kV microscopes, and biophysical/biochemical characterization of target-ligand interactions. A proprietary site-specific cross-linking technology enables stabilization of transient and unstable protein–DNA/RNA complexes that resist standard co-crystallization. Leaderna positions as the first commercial cryo-EM provider in Poland and is built around a small bench of domain experts (CEO Kustosz, CSO Agnieszka Napiórkowska, CFO Sylwester Pobiarzyn, BD Przemysław Putno), with deep ties to the International Institute of Molecular and Cell Biology in Warsaw and Polish science centers.

Commercially, Leaderna operates a B2B service model selling directly to pharmaceutical companies across Poland, the Netherlands, and the United States. Revenue is generated through project-based structure-determination engagements priced under a risk-sharing model (preliminary experiments at operational cost, with success-fee structuring upon satisfactory delivery), supplemented by an EU funds assistance service where Leaderna acts as co-contractor or subcontractor on grant-funded crystallography programs. The named customer base spans IONIS Pharmaceuticals, UbiQ Bio, Adamed Pharma, Celon Pharma, OncoArendi Therapeutics, and Selvita, with cumulative disclosed project outputs of 13 protein-inhibitor structures solved for OncoArendi (whose OATD-01 compound is in clinical trials for sarcoidosis) and four structures solved for Adamed.

Leaderna Biostructures firmographics

Firmographics
Name
Leaderna Biostructures
Legal name
Leaderna Biostructures Sp. z o.o.
Website
https://leaderna.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Leaderna Biostructures is a Warsaw-based structural biology CRO providing X-ray crystallography and cryo-EM services (Gene-to-Structure pipeline) to pharmaceutical and biotechnology companies for structure-based drug design, with specialization in protein-nucleic acid complexes and a risk-sharing, success-fee pricing model.
Ownership category
akta.pro rank

Leaderna Biostructures industry classification

Industry
Product category
Structural Biology Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Structural biology services
  • X-ray crystallography
  • Cryo-EM services
  • Protein structure analysis
  • Drug discovery services

Where Leaderna Biostructures is headquartered

Location

Headquarters

HQ city
Warsaw
HQ country
Poland
HQ region
Europe

Offices1 record

Markets served

Leaderna Biostructures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Structural Biology Services: Service-based revenue from X-ray crystallography and cryo-EM analysis, including protein production, crystallization, structure determination, and biophysical characterization. Projects start with feasibility assessment followed by preliminary experiments at operational cost (risk-sharing model), with final payment as success fee upon satisfactory delivery.
  2. EU Funded Project Services: Assistance in obtaining EU funds for crystallography-based drug discovery, where Leaderna serves as co-contractor or subcontractor.

Go-to-market motion2 records

Distribution channels1 record

Leaderna Biostructures product offering

Product offering

Core offering

Leaderna Biostructures delivers Gene-to-Structure structural biology services for pharmaceutical and biotechnology drug discovery, covering gene construct design, recombinant protein production, crystallization, X-ray diffraction, cryo-EM analysis, and biophysical/biochemical characterization of protein-ligand interactions. The company specializes in structure-based drug design, with particular expertise in protein-nucleic acid complexes developed through cooperation with Ionis Pharmaceuticals.

Product overview

Leaderna Biostructures offers a unified service platform called Gene-to-Structure that provides end-to-end structural biology solutions for drug discovery. The platform integrates multiple service modules: Preparation of Expression Constructs, Recombinant Protein Production, X-ray Crystallography, Single-Particle Cryo-EM, and Biophysical and Biochemical Assays. A proprietary Unique Cross-linking Technology enables analysis of challenging protein-nucleic acid complexes. The services support structure-based drug design, hit-to-lead optimization, and lead optimization, with emphasis on nucleic acid-based therapeutics. Leaderna also provides EU Funds Assistance as a supporting service for funding applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gene-to-Structure Services Comprehensive end-to-end structural biology service covering gene construct design, recombinant protein expression and purification, crystallization, X-ray diffraction and cryo-EM data collection, structure determination and refinement, and biophysical and biochemical characterization of target-ligand interactions. Designed for pharmaceutical and biotechnology companies engaged in structure-based drug design, hit-to-lead optimization, and lead optimization.
  • EU Funds Assistance Services Service that assists small and medium pharmaceutical companies in obtaining EU funding for crystallography-based new molecule discovery projects. Leaderna collaborates with technology transfer centers and serves as co-contractor or subcontractor in EU-funded projects, providing structural biology expertise within grant-funded drug discovery consortia.

Quantifiable outcome

  • Minimizes screening of thousands or millions of chemicals for protein tailoring
  • +2 more outcomes

Companies that use Leaderna Biostructures

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Leaderna Biostructures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Leaderna Biostructures partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • IONIS PharmaceuticalscoreStrategic or Co-development PartnerStrategic collaboration for solving protein-nucleic acid drug structures and joint patent development. This partnership expanded Leaderna's expertise in structure determination of nucleic acid-based drugs with proteins, positioning the company as a specialist in RNA-targeted therapeutics structural analysis.
  • UbiQ BiocoreStrategic or Co-development PartnerCollaboration for solving protein-inhibitor structures and scientific cooperation using cryo-EM technology.
  • Adamed PharmacoreStrategic or Co-development PartnerPartnership for solving protein-inhibitor structures. Four structures have been solved with results to be published.
  • Celon PharmacoreStrategic or Co-development PartnerCollaboration on protein production and biophysical characterization under the prestigious InnoNeuroPharm NCBR grant.
  • OncoArendi TherapeuticscoreStrategic or Co-development PartnerPartnership for solving protein-inhibitor structures. 13 structures have been solved with results to be published. The OATD-01 compound from this collaboration is in clinical trials as a potential first-in-class sarcoidosis drug.
  • SelvitaminorStrategic or Co-development PartnerCooperation in structure-based drug design projects with leading pharmaceutical company in central Europe.
  • Polish Science CenterscoreStrategic or Co-development PartnerClose collaboration with renowned experts and distinguished scientists in structural biology from Polish science centers, enabling execution of challenging projects.
  • International Institute of Molecular and Cell Biology in Warsaw (IIMCB)coreStrategic or Co-development PartnerFounder Pawel Kustosz led the IIMCB Structure Biology Center from 2015-2020. The company operates from the University of Warsaw Biological and Chemical Research Centre, maintaining close ties with this research institution.
  • Technology Transfer CentersminorGTM or Marketing PartnerCooperation with technology transfer centers to assist clients in obtaining EU funds for crystallography-based drug discovery projects.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Leaderna Biostructures competitors and assessment

Company assessment

Direct peers

  • Proteros Biostructures: Germany-based structural biology CRO offering X-ray crystallography and cryo-EM services for structure-based drug design; closest direct competitor to Leaderna with similar end-to-end structural biology workflow and pharma/biotech customer base.
  • Creative Biostructure: Structural biology services provider offering protein crystallization, X-ray crystallography, cryo-EM, and protein production — directly competing in the same commercial service category as Leaderna.
  • SARomics Biostructures: Sweden-based CRO specializing in protein crystallography, cryo-EM, and biophysical characterization for drug discovery — directly comparable service offering and target customers to Leaderna.

Broad incumbents

  • Evotec: Global drug discovery CRO with structural biology and protein sciences capabilities embedded within its integrated discovery platform — broad incumbent overlapping with Leaderna's structure-based drug design services.
  • Sygnature Discovery: UK-based integrated drug discovery CRO with structural biology, biophysics, and medicinal chemistry services — competes with Leaderna for structural biology engagements within broader discovery programs.
  • Charles River Laboratories: Large global CRO offering structural biology and drug discovery services as part of a much broader portfolio; competes with Leaderna for enterprise pharma structural biology budgets but at significantly greater scale.
  • WuXi AppTec (STA Pharmaceutical): Large China-based discovery and development services organization with structural biology capabilities; competes in the structural biology services market and serves global pharma clients.
  • HitGen / Vernalis: Drug discovery company with heritage in structure-based design (Vernalis) and integrated with HitGen's platform; offers structure-based design services comparable to Leaderna's niche.

Others

Regional players

  • Life Sciences Discovery (e.g., Concept Life Sciences / Domainex): UK-based discovery CROs with structural biology and protein science capabilities; comparable service offerings to Leaderna but operating in a different European geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Leaderna Biostructures social profiles

Digital presence

Leaderna Biostructures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Leaderna Biostructures leadership team

Management profile

Number of profiles

Profiles5 records

Leaderna Biostructures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Leaderna Biostructures M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leaderna Biostructures

What does Leaderna Biostructures do?

Leaderna Biostructures delivers Gene-to-Structure structural biology services for pharmaceutical and biotechnology drug discovery, covering gene construct design, recombinant protein production, crystallization, X-ray diffraction, cryo-EM analysis, and biophysical/biochemical characterization of protein-ligand interactions. The company specializes in structure-based drug design, with particular expertise in protein-nucleic acid complexes developed through cooperation with Ionis Pharmaceuticals.

Is Leaderna Biostructures a public or private company?

Leaderna Biostructures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Leaderna Biostructures founded?

Leaderna Biostructures was founded in 2020. It employs 1 to 10 people.

Where is Leaderna Biostructures based?

Leaderna Biostructures is headquartered in Warsaw, Poland, in the Europe region.

How does Leaderna Biostructures make money?

Two revenue lines are on record. Structural Biology Services are the primary driver. The others are EU Funded Project Services.

Who are Leaderna Biostructures's main competitors?

Direct peers on record are Proteros Biostructures, Creative Biostructure and SARomics Biostructures. Broad incumbents are Evotec, Sygnature Discovery, Charles River Laboratories, WuXi AppTec (STA Pharmaceutical) and HitGen / Vernalis. University of Warsaw Biological and Chemical Research Centre (CNBCh UW) is listed as an others. Life Sciences Discovery (e.g., Concept Life Sciences / Domainex) is listed as a regional player.

Does Leaderna Biostructures have an API?

No public API is recorded for Leaderna Biostructures.

What industry is Leaderna Biostructures in?

Leaderna Biostructures's product category is Structural Biology Services. Its primary akta.pro industry code is HLAAAIAH, Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales